Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study

BACKGROUND: GnRHa treatment was established for improving final adult height (FAH) in children presenting with Idiopathic central precocious puberty (ICPP) up to age 8, while several controversies remained for older age groups. The primary objective was to evaluate whether boys diagnosed with ICPP o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Ming-ming, Yang, Shu-ting, Wu, Wen-wen, Wang, Shan-shan, Li, Man, Liu, Qing-qing, Ji, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716691/
https://www.ncbi.nlm.nih.gov/pubmed/36456936
http://dx.doi.org/10.1186/s12902-022-01207-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716691/
https://www.ncbi.nlm.nih.gov/pubmed/36456936
http://dx.doi.org/10.1186/s12902-022-01207-z

Ejemplares similares